Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pritumumab - Nascent Biotech

Next Previous
Drug Profile

Pritumumab - Nascent Biotech

Alternative Names: ACA 11; CLN-IgG; CLNH 11; Monoclonal antibody ACA 11

Latest Information Update: 28 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California, San Diego
  • Developer Nascent Biotech
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioma
  • No development reported Brain cancer; COVID 2019 infections; Pancreatic cancer

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for phase-I development in Brain-cancer(Metastatic disease, Recurrent, Second-line therapy or greater) in USA (IV, Infusion)
  • 28 Apr 2024 No recent reports of development identified for research development in COVID-2019-infections in USA (Parenteral)
  • 29 Nov 2023 Nascent Biotech receives Notice of Allowance for a Method of Use patent for pritumumab in Japan

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top